Key result
Sitagliptin augmented the hypotensive response to 5 mg of enalapril (P=0.05) but attenuated the hypotensive response to 10 mg of enalapril (P=0.02) in subjects with metabolic syndrome.
Why the study?
Does sitagliptin alter the hemodynamic response to acute enalapril administration in subjects with metabolic syndrome?
Population
24 subjects with the metabolic syndrome
Comparison
Sitagliptin 100 mg/day for 5 days combined with… vs Matching placebo for 5 days combined with acute…
Design
RCT, randomized, cross-over fashion, matching placebo
Follow-up
5 days per cross-over period
Authors
Loading...
Alerts to dose-dependent BP effects with sitagliptin plus enalapril; confirms interaction in human metabolic syndrome.
RCT (n=24)
Placebo-controlled
Cross-over
Does sitagliptin alter the hemodynamic response to acute enalapril administration in subjects with metabolic syndrome?
Sitagliptin interacts with ACE inhibition in humans, augmenting hypotension at submaximal ACEi doses but activating the sympathetic nervous system to diminish hypotension at maximal ACEi doses.
Marney et al. (2010) conducted an RCT in Metabolic syndrome (n=24). Sitagliptin vs. Placebo was evaluated on Blood pressure response to acute ACE inhibition (enalapril). Sitagliptin augmented the hypotensive response to 5 mg of enalapril (P=0.05) but attenuated the hypotensive response to 10 mg of enalapril (P=0.02) in subjects with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: